Followers | 17 |
Posts | 4299 |
Boards Moderated | 0 |
Alias Born | 04/13/2016 |
Sunday, November 29, 2020 9:24:17 AM
I’m not sure you understand how silk farming works, nor how scaling a new business happens.
First, I doubt that KBLB will share contract information with shareholders. Thus even when sales happen, the contracts will remain a secret.
Next, you appear to portray the situation as if the customers are in charge of the ‘quantities requested.’ But companies will have to work with KBLB to determine what quantities the company can produce. If a company wants 40 metric tons in the next 6 months, KBLB can’t produce that much. If they want 80 metric tons by the end of 2021, KBLB can’t produce that much.
KBLB’s production is limited by: 1) the number of eggs sent over; 2) their ability to rear silkworms off-season; 3) the amount of mulberry they can obtain; 4) the size of the facility at Prodigy.
Knowing how many eggs were sent over helps investors to understand how quickly they can ramp up production, assuming ample supplies and space. The capacity of Prodigy has been estimated at 40 metric tons per year, once they reach full capacity.
For the moment, these limitations, not the contracts the company has, will govern production at Prodigy.
Recent KBLB News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:31:54 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/16/2023 09:30:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:43:51 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/11/2023 08:30:50 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/08/2023 04:15:15 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/01/2023 08:30:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:35:05 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM